Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Tom-Lin"

12 News Found

Pfizer Q1 2025 revenue drops 8% to $13.7 billion
News | April 29, 2025

Pfizer Q1 2025 revenue drops 8% to $13.7 billion

Delivers robust earnings performance, successfully navigating a dynamic environment


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
People | February 23, 2025

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025


Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
News | August 23, 2024

Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24

Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line


Sun Pharma joins hands with WOTR to create water harvesting capacity in Maharashtra
News | November 13, 2023

Sun Pharma joins hands with WOTR to create water harvesting capacity in Maharashtra

This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change


Syngene to acquire multi-modal facility from Stelis Biopharma
News | July 05, 2023

Syngene to acquire multi-modal facility from Stelis Biopharma

Adding 20,000 liters of installed biologics drug substance manufacturing capacity


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


SpeeDx and SynGenis partner for custom oligonucleotide synthesis
Supply Chain | September 28, 2021

SpeeDx and SynGenis partner for custom oligonucleotide synthesis

The investment will increase SpeeDx internal capacity to scale up manufacturing


Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
News | August 11, 2021

Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22

The company has tied up with OrbiMed as a financial partner for global reach


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.